Scarica l'app Stockscreener
23.07
5.87%
1.28
Dopo l'orario di chiusura:
22.40
-0.67
-2.90%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DYN Giù?
Forum
Previsione
Precedente Chiudi:
$21.79
Aprire:
$21.92
Volume 24 ore:
2.16M
Relative Volume:
1.24
Capitalizzazione di mercato:
$3.81B
Reddito:
-
Utile/perdita netta:
$-451.71M
Rapporto P/E:
-7.151
EPS:
-3.2261
Flusso di cassa netto:
$-462.19M
1 W Prestazione:
+11.94%
1M Prestazione:
+33.82%
6M Prestazione:
+24.70%
1 anno Prestazione:
+158.05%
Intervallo 1D:
$21.82
$23.11
Intervallo di 1 settimana:
$20.42
$23.11
Portata 52W:
$8.06
$25.00
Dyne Therapeutics Inc Stock (DYN) Company Profile
Nome
Dyne Therapeutics Inc
Settore
Industria
Telefono
(781) 786-8230
Indirizzo
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
23.07 | 3.67B | 0 | -451.71M | -462.19M | -3.2261 |
VRTX
Vertex Pharmaceuticals Inc
|
528.04 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
654.27 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
939.68 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.78 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.24 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-10 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-10-10 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-25 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | Iniziato | Bernstein | Mkt Perform |
| 2025-06-11 | Ripresa | Raymond James | Outperform |
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-05-29 | Iniziato | Evercore ISI | Outperform |
| 2025-03-12 | Iniziato | BMO Capital Markets | Outperform |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-13 | Iniziato | Robert W. Baird | Outperform |
| 2024-11-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-10-24 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-05-21 | Reiterato | Chardan Capital Markets | Buy |
| 2024-04-30 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-20 | Iniziato | H.C. Wainwright | Buy |
| 2023-02-27 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | Iniziato | Oppenheimer | Outperform |
| 2023-01-26 | Iniziato | Guggenheim | Buy |
| 2022-07-20 | Iniziato | Chardan Capital Markets | Buy |
| 2022-07-12 | Iniziato | Raymond James | Outperform |
| 2020-10-12 | Iniziato | JP Morgan | Overweight |
| 2020-10-12 | Iniziato | Jefferies | Buy |
| 2020-10-12 | Iniziato | Piper Sandler | Overweight |
| 2020-10-12 | Iniziato | Stifel | Buy |
Mostra tutto
Dyne Therapeutics Inc Borsa (DYN) Ultime notizie
Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026? - The Motley Fool
Dyne therapeutics director Jason Rhodes sells $10.7m in stock - Investing.com UK
Dyne therapeutics director Jason Rhodes sells $10.7m in stock By Investing.com - Investing.com South Africa
Dyne Therapeutics(DYN.US) Director Sells US$10.71 Million in Common Stock - Moomoo
Form 4 Dyne Therapeutics Inc For: 30 June By Investing.com - Investing.com Canada
Atlas funds linked to Dyne (DYN) director sell 504,695 shares - Stock Titan
Myotonic Dystrophy Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma, Lupin, AMO Pharma - Barchart.com
Form 144 Dyne Therapeutics For: 29 June By Investing.com - Investing.com South Africa
Bronstein, Gewirtz & Grossman, LLC Encourages Dyne Therapeutics - The National Law Review
Form 144 Dyne Therapeutics For: 26 June By Investing.com - Investing.com Nigeria
Price to sales forward of Dyne Therapeutics, Inc. – NASDAQ:DYN - TradingView
DYN Initiated Coverage by TD Cowen -- Rating Set to Buy - GuruFocus
Enterprise value to EBIT forward of Dyne Therapeutics Inc – BX:DYN - TradingView
Dyne therapeutics director Jason P Rhodes sells $5.65m in stock - Investing.com UK
Price to earnings forward of Dyne Therapeutics, Inc. – NASDAQ:DYN - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Price to earnings forward of Dyne Therapeutics Inc – BX:DYN - TradingView
Form 4 Dyne Therapeutics Inc For: 26 June By Investing.com - Investing.com Australia
Enterprise value to revenue forward of Dyne Therapeutics Inc – BX:DYN - TradingView
[144] Dyne Therapeutics, Inc. SEC Filing - Stock Titan
Dyne Therapeutics (NASDAQ: DYN) CFO sells 2,362 shares to cover taxes - Stock Titan
Dyne Therapeutics(DYN.US) Director Sells US$5.65 Million in Common Stock - Moomoo
Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Dyne Therapeutics Insider Sold Shares Worth $5,646,497, According to a Recent SEC Filing - marketscreener.com
TD Cowen Initiates Dyne Therapeutics at Buy - Moomoo
TD Cowen Initiates Dyne Therapeutics(DYN.US) With Buy Rating - Moomoo
Dyne Therapeutics stock initiated at buy by TD Cowen on platform - Investing.com UK
Dyne Therapeutics stock initiated at buy by TD Cowen on platform By Investing.com - Investing.com Australia
Dyne Therapeutics (DYN) director-linked funds sell 267,760 shares - Stock Titan
Form 144 Dyne Therapeutics For: 25 June By Investing.com - Investing.com Nigeria
Dyne Therapeutics Inc Actuals & Estimates (NASDAQ:DYN) - TradingView
How (DYN) Movements Inform Risk Allocation Models - Stock Traders Daily
Erick Lucera files Form 144 to sell DYN shares (DYN) - Stock Titan
DYN Forecast — Price Target — Prediction for 2027 - TradingView
Dyne Therapeutics (DYN) Adds Barry Greene And Expands Funding, Is The Stock Still A Bargain? - Sahm
Dyne Therapeutics director Kersten sells $5.46 million in shares By Investing.com - Investing.com South Africa
Dyne Therapeutics director Kersten sells $5.46 million in shares - Investing.com UK
Form 4 Dyne Therapeutics Inc For: 24 June By Investing.com - Investing.com Nigeria
Form 144 Dyne Therapeutics For: 24 June By Investing.com - Investing.com South Africa
Dyne Therapeutics Insider Sold Shares Worth $5,464,611, According to a Recent SEC Filing - Moomoo
Dyne Therapeutics(DYN.US) Director Sells US$5.46 Million in Common Stock - Moomoo
Dyne Therapeutics (DYN) director-affiliated fund sells 263,962 shares under 10b5-1 plan - Stock Titan
Dyne Therapeutics Inc Azioni (DYN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Dyne Therapeutics Inc Azioni (DYN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Rhodes Jason P | Director |
Jun 29 '26 |
Sale |
21.14 |
195,427 |
4,131,327 |
975,931 |
3.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):